J Chew1, L Tay, J P Lim, B P Leung, A Yeo, S Yew, Y Y Ding, W S Lim. 1. Dr Justin Chew, Department of Geriatric Medicine, 11 Jalan Tan Tock Seng, Tan Tock Seng Hospital, Singapore 308433, Email: justin_chew@ttsh.com.sg.
Abstract
OBJECTIVES: (i) To investigate serum myostatin (absolute and normalized for total body lean mass (TBLM)) and IGF-1 as biomarkers of frailty and low relative appendicular skeletal muscle mass (RASM) in older adults, and; (ii) to examine gender differences in the association of serum myostatin and IGF-1 levels with frailty and low RASM. DESIGN: Cross-sectional study. SETTING: The "Longitudinal Assessment of Biomarkers for characterization of early Sarcopenia and predicting frailty and functional decline in community-dwelling Asian older adults Study" (GERI-LABS) study in Singapore. PARTICIPANTS: 200 subjects aged 50 years and older residing in the community. MEASUREMENTS: Frailty was assessed using the modified Fried criteria. Low RASM was defined using cutoffs for height-adjusted appendicular skeletal muscle mass measured by dual-energy X-ray absorptiometry as recommended by the Asian Working Group for Sarcopenia. Comorbidities, cognitive and functional performance, physical activity and nutritional status were assessed. Blood samples collected included serum myostatin, insulin-like growth factor 1 (IGF-1) and markers of inflammation (total white cell count, CRP, IL-6 and TNFaR1). Subjects were classified into 4 groups: Frail/Prefrail with low RASM (Frail/Low RASM), Frail/Prefrail with normal RASM (Frail/Normal RASM), Robust with low RASM (Robust/Low RASM) and Robust with normal RASM (Robust/Normal RASM). RESULTS: 63 (32%) subjects were classified as Frail/Low RASM, 53 (27%) Frail/Normal RASM, 28 (14%) Robust/Low RASM and 56 (28%) Robust/Normal RASM respectively. Frail/Low RASM subjects were older and had lower BMI compared to Frail/Normal RASM and robust subjects. Mean (SE) normalized myostatin levels were higher in Frail/Low RASM compared to Frail/Normal RASM subjects (1.0 (0.04) versus 0.84 (0.05) ng/ml/kg, P=0.01). Median (IQR) IGF-1 level was lower amongst Frail/Low RASM subjects compared to Frail/Normal RASM subjects (102.3, (77.7, 102.5) vs 119.7 (82.7, 146.0) ng/ml, P=0.046). No differences in myostatin or IGF-1 were observed among robust individuals with or without low muscle mass. In adjusted multinomial logistic regression models with Robust/Normal RASM as the reference group, myostatin (P=0.05) and IGF-1 (P=0.043) were associated with Frail/Low RASM status in the whole cohort. When stratified by gender, myostatin was significantly associated with Frail/Low RASM status in men only (P=0.03). In women, serum IGF-1 was associated with Frail/Low RASM status (P=0.046), but not myostatin (P=0.53). CONCLUSION: Serum myostatin, normalized for TBLM in men and IGF-1 in women are potential biomarkers for frail individuals with low RASM, and may identify a target group for intervention.
OBJECTIVES: (i) To investigate serum myostatin (absolute and normalized for total body lean mass (TBLM)) and IGF-1 as biomarkers of frailty and low relative appendicular skeletal muscle mass (RASM) in older adults, and; (ii) to examine gender differences in the association of serum myostatin and IGF-1 levels with frailty and low RASM. DESIGN: Cross-sectional study. SETTING: The "Longitudinal Assessment of Biomarkers for characterization of early Sarcopenia and predicting frailty and functional decline in community-dwelling Asian older adults Study" (GERI-LABS) study in Singapore. PARTICIPANTS: 200 subjects aged 50 years and older residing in the community. MEASUREMENTS: Frailty was assessed using the modified Fried criteria. Low RASM was defined using cutoffs for height-adjusted appendicular skeletal muscle mass measured by dual-energy X-ray absorptiometry as recommended by the Asian Working Group for Sarcopenia. Comorbidities, cognitive and functional performance, physical activity and nutritional status were assessed. Blood samples collected included serum myostatin, insulin-like growth factor 1 (IGF-1) and markers of inflammation (total white cell count, CRP, IL-6 and TNFaR1). Subjects were classified into 4 groups: Frail/Prefrail with low RASM (Frail/Low RASM), Frail/Prefrail with normal RASM (Frail/Normal RASM), Robust with low RASM (Robust/Low RASM) and Robust with normal RASM (Robust/Normal RASM). RESULTS: 63 (32%) subjects were classified as Frail/Low RASM, 53 (27%) Frail/Normal RASM, 28 (14%) Robust/Low RASM and 56 (28%) Robust/Normal RASM respectively. Frail/Low RASM subjects were older and had lower BMI compared to Frail/Normal RASM and robust subjects. Mean (SE) normalized myostatin levels were higher in Frail/Low RASM compared to Frail/Normal RASM subjects (1.0 (0.04) versus 0.84 (0.05) ng/ml/kg, P=0.01). Median (IQR) IGF-1 level was lower amongst Frail/Low RASM subjects compared to Frail/Normal RASM subjects (102.3, (77.7, 102.5) vs 119.7 (82.7, 146.0) ng/ml, P=0.046). No differences in myostatin or IGF-1 were observed among robust individuals with or without low muscle mass. In adjusted multinomial logistic regression models with Robust/Normal RASM as the reference group, myostatin (P=0.05) and IGF-1 (P=0.043) were associated with Frail/Low RASM status in the whole cohort. When stratified by gender, myostatin was significantly associated with Frail/Low RASM status in men only (P=0.03). In women, serum IGF-1 was associated with Frail/Low RASM status (P=0.046), but not myostatin (P=0.53). CONCLUSION: Serum myostatin, normalized for TBLM in men and IGF-1 in women are potential biomarkers for frail individuals with low RASM, and may identify a target group for intervention.
Authors: A Ratkevicius; A Joyson; I Selmer; T Dhanani; C Grierson; A M Tommasi; A DeVries; P Rauchhaus; D Crowther; S Alesci; P Yaworsky; F Gilbert; T W Redpath; J Brady; K C H Fearon; D M Reid; C A Greig; H Wackerhage Journal: J Gerontol A Biol Sci Med Sci Date: 2011-03-07 Impact factor: 6.053
Authors: Trevor N Stitt; Doreen Drujan; Brian A Clarke; Frank Panaro; Yekatarina Timofeyva; William O Kline; Michael Gonzalez; George D Yancopoulos; David J Glass Journal: Mol Cell Date: 2004-05-07 Impact factor: 17.970
Authors: Peggy M Cawthon; Eric S Orwoll; Katherine E Peters; Kristine E Ensrud; Jane A Cauley; Deborah M Kado; Marcia L Stefanick; James M Shikany; Elsa S Strotmeyer; Nancy W Glynn; Paolo Caserotti; Mahalakshmi Shankaran; Marc Hellerstein; Steven R Cummings; William J Evans Journal: J Gerontol A Biol Sci Med Sci Date: 2019-05-16 Impact factor: 6.053
Authors: H Robert Bergen; Joshua N Farr; Patrick M Vanderboom; Elizabeth J Atkinson; Thomas A White; Ravinder J Singh; Sundeep Khosla; Nathan K LeBrasseur Journal: Skelet Muscle Date: 2015-07-15 Impact factor: 4.912
Authors: Athan G Dial; Cynthia M F Monaco; Grace K Grafham; Nadya Romanova; Jeremy A Simpson; Mark A Tarnopolsky; Christopher G R Perry; Evangelia Kalaitzoglou; Thomas J Hawke Journal: Physiol Rep Date: 2020-07
Authors: Kalene Pek; Justin Chew; Jun Pei Lim; Suzanne Yew; Cai Ning Tan; Audrey Yeo; Yew Yoong Ding; Wee Shiong Lim Journal: Int J Environ Res Public Health Date: 2020-06-14 Impact factor: 3.390
Authors: Frank Klont; Lyanne M Kieneker; Antonio W Gomes-Neto; Suzanne P Stam; Nick H T Ten Hacken; Ido P Kema; André P van Beek; Else van den Berg; Péter Horvatovich; Rainer Bischoff; Stephan J L Bakker Journal: J Clin Med Date: 2020-01-21 Impact factor: 4.241